AU Patent

AU2016244279A1 — Method of adjuvant cancer treatment

Assigned to Novartis AG · Expires 2016-11-03 · 10y expired

What this patent protects

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

USPTO Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: AU2016244279A1
Jurisdiction: AU
Classification: —
Expires: 2016-11-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.